Time To Efficacy and Onset Of Action Of Linezolid
Information source: Pfizer
Information obtained from ClinicalTrials.gov on June 20, 2008
Link to the current ClinicalTrials.gov record.
Condition(s) targeted: Gram-Positive Bacterial Infections; Skin and Connective Tissue Diseases
Intervention: linezolid (Drug)
Phase: Phase 4
Status: Completed
Sponsored by: Pfizer Official(s) and/or principal investigator(s):
Pfizer CT.gov Call Center, Study Director, Affiliation: Pfizer
Summary
To assess the onset of action of linezolid
Clinical Details
Official title: Time To Efficacy and Onset Of Action Of Linezolid In Skin and Soft Tissue Infections
Study design: Treatment, Randomized, Open Label, Active Control, Parallel Assignment, Efficacy Study
Primary outcome: Time to defervescence
Secondary outcome: Reduction of CRP levels
Reduction of leucocyte count
Eligibility
Minimum age: 18 Years.
Maximum age: N/A.
Gender(s): Both.
Criteria:
Inclusion Criteria:
- suspected grampositive infection
- fever > 38 C
Exclusion Criteria:
- Infections to be treated successfully by surgical procedures
Locations and Contacts
Additional Information
Link to ClinicalStudyResults.org posting
Starting date: June 2003
Ending date: June 2005
Last updated: August 10, 2007
|
